GlassScriptPhysician profile
Sheraj Jacob
NPI 1821047176
$9,829.32
in general payments reported to CMS, 2019-2025
42 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $585 · 2021: $1,365 · 2022: $1,755 · 2023: $1,937 · 2024: $1,289 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846 · Education: $29.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,846.10 |
| Education | $29.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,319.03 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $954.46 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $662.49 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $496.18 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $413.41 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $407.58 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $396.22 | 2022-2025 | |
| Gilead Sciences, INC. | $388.54 | 2019-2025 | |
| Celgene Corporation | $260.92 | 2021-2024 | Zeposia |
| Pfizer INC. | $232.29 | 2019-2025 | |
| Amgen INC. | $224.76 | 2020-2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $192.46 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $190.39 | 2019-2024 | Linzess |
| Ucb, INC. | $176.23 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $171.78 | 2021-2024 | Interstim, Nexpowder |
| Daiichi Sankyo INC. | $169.08 | 2019-2023 | Injectafer |
| Shire North American Group INC | $125.00 | 2019 | |
| Lilly USA, LLC | $111.19 | 2024-2025 | Omvoh, Zepbound |
| Phathom Pharmaceuticals, INC. | $63.39 | 2024-2025 | Voquezna |
| Olympus America INC. | $61.82 | 2019-2023 | Evis Exera Lll Colonovideoscope |
| Organon LLC | $60.72 | 2022-2025 | Hadlima, Renflexis |
| Shionogi INC | $60.43 | 2019 | |
| Stryker Corporation | $59.57 | 2023 | 1688 |
| Boston Scientific Corporation | $58.77 | 2024-2025 | Watchman Flx, Captivator II |
| Celltrion USA INC. | $50.72 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $50.31 | 2020-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.14 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $36.83 | 2025 | Iqirvo |
| Endo Pharmaceuticals INC. | $34.83 | 2019 | |
| Fresenius Kabi USA, LLC | $33.01 | 2023 | Idacio |
| Allergan, INC. | $28.45 | 2019 | |
| Qol Medical, LLC | $25.05 | 2021 | |
| Mauna Kea Technologies, INC. | $20.84 | 2023 | |
| Novo Nordisk INC | $20.08 | 2025 | Wegovy |
| Intra-Sana Laboratories | $18.48 | 2021-2022 | |
| Madrigal Pharmaceuticals | $17.78 | 2024 | Resmetirom |
| Vivus LLC | $16.43 | 2021 | |
| Ethicon US, LLC | $15.00 | 2021 | |
| Redhill Biopharma INC. | $14.59 | 2020 | |
| Sandoz INC. | $14.51 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $13.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheraj Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.